CR20220582A - Anticuerpos anti-dectina-2 - Google Patents

Anticuerpos anti-dectina-2

Info

Publication number
CR20220582A
CR20220582A CR20220582A CR20220582A CR20220582A CR 20220582 A CR20220582 A CR 20220582A CR 20220582 A CR20220582 A CR 20220582A CR 20220582 A CR20220582 A CR 20220582A CR 20220582 A CR20220582 A CR 20220582A
Authority
CR
Costa Rica
Prior art keywords
methods
binding agents
dectin
inventive
nucleic acids
Prior art date
Application number
CR20220582A
Other languages
English (en)
Inventor
David Dornan
Shelley Erin Ackerman
Karla A Henning
Justin A Kenkel
Original Assignee
Bolt Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bolt Biotherapeutics Inc filed Critical Bolt Biotherapeutics Inc
Publication of CR20220582A publication Critical patent/CR20220582A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a los agentes de unión a la lectina de tipo C asociada a células dendríticas 2 (Dectin-2), a los ácidos nucleicos que comprenden los agentes de unión inventivos, a los vectores y a las células que comprenden los ácidos nucleicos inventivos, y a las composiciones de los mismos. La invención también se refiere a métodos para proporcionar los agentes de unión inventivos, métodos para tratar una enfermedad, trastorno o afección en un mamífero y métodos para estimular una célula presentadora de antígeno
CR20220582A 2020-05-01 2021-05-03 Anticuerpos anti-dectina-2 CR20220582A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063018952P 2020-05-01 2020-05-01
PCT/US2021/030466 WO2021222894A1 (en) 2020-05-01 2021-05-03 Anti-dectin-2 antibodies

Publications (1)

Publication Number Publication Date
CR20220582A true CR20220582A (es) 2023-01-09

Family

ID=76076494

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220582A CR20220582A (es) 2020-05-01 2021-05-03 Anticuerpos anti-dectina-2

Country Status (13)

Country Link
US (3) US11753474B2 (es)
EP (1) EP4142881A1 (es)
JP (1) JP2023524092A (es)
KR (1) KR20230005907A (es)
CN (1) CN115461122A (es)
AU (1) AU2021262828A1 (es)
BR (1) BR112022020639A2 (es)
CA (1) CA3175576A1 (es)
CL (1) CL2022003012A1 (es)
CR (1) CR20220582A (es)
IL (1) IL297782A (es)
MX (1) MX2022013616A (es)
WO (1) WO2021222894A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017211321A1 (zh) * 2016-06-08 2017-12-14 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2024216089A1 (en) * 2023-04-13 2024-10-17 Bolt Biotherapeutics, Inc. Anti-dectin-2 antibody combination therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US7071171B1 (en) * 1996-12-20 2006-07-04 Board Of Regents The University Of Texas System Unique dendritic cell-associated c-type lectins, dectin-1 and dectin-2 compositions and uses thereof
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
WO2006073921A2 (en) 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US9676863B2 (en) 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
PL3129067T3 (pl) 2014-03-19 2023-05-08 Genzyme Corporation Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
WO2017117269A1 (en) * 2015-12-29 2017-07-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for dectin-2 stimulation and cancer immunotherapy
WO2018029586A1 (en) 2016-08-07 2018-02-15 Novartis Ag Mrna-mediated immunization methods
WO2018140831A2 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
EP3645043A4 (en) * 2017-06-28 2021-04-07 The Board of Trustees of the Leland Stanford Junior University METHODS AND COMPOSITIONS FOR DECTIN 2 STIMULATION AND CANCER IMMUNOTHERAPY
EP3947467A4 (en) 2019-04-05 2023-01-04 Dren Bio, Inc. PROCEDURE FOR DEPLETION OF pathogens by antibody-directed phagocytosis
IL301956A (en) 2020-10-07 2023-06-01 Dren Bio Inc Antibodies against dectin-1 and methods of using them

Also Published As

Publication number Publication date
US20230406939A1 (en) 2023-12-21
CA3175576A1 (en) 2021-11-04
JP2023524092A (ja) 2023-06-08
US12325750B2 (en) 2025-06-10
BR112022020639A2 (pt) 2022-11-29
MX2022013616A (es) 2022-11-16
AU2021262828A1 (en) 2022-11-03
US11753474B2 (en) 2023-09-12
CL2022003012A1 (es) 2023-06-23
IL297782A (en) 2022-12-01
WO2021222894A1 (en) 2021-11-04
EP4142881A1 (en) 2023-03-08
US20220153849A1 (en) 2022-05-19
CN115461122A (zh) 2022-12-09
US20250270329A1 (en) 2025-08-28
KR20230005907A (ko) 2023-01-10

Similar Documents

Publication Publication Date Title
MX2022013616A (es) Anticuerpos anti-dectina-2.
CY1122576T1 (el) Ανθρωπινα αντισωματα που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (leg-3), και χρησεις εξ' αυτων
PH12021551484A1 (en) Antibodies binding to cd3
US20250206793A1 (en) T-cell expansion method and uses
MX2024003355A (es) Anticuerpos anti-cd3.
PE20210517A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
EA202091219A1 (ru) Культивирование плаценты с целью выделения экзосом
MX2025012685A (es) Anticuerpos para claudin6 y metodos para tratar el cancer
IL161832A0 (en) Pharmaceutical composition for inducing an immune response in a human or animal
BR112018076306A2 (pt) composições e métodos para a supressão de células cd117+
BR112013014265A8 (pt) sequência de ácido nucleico isolada, receptor antígeno quimérico isolado, célula, vetor, e, métodos para estimular uma resposta imune mediada por célula t, para fornecer uma imunidade antitumoral em um mamífero, para tratar um mamífero tendo uma doença, distúrbio ou condição, para tratar um ser humano com uma doença, para gerar uma população persistente de célula t, e para expandir uma população de célula t
MX2022015204A (es) Anticuerpos que se unen a cd3.
PH12021553254A1 (en) Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
MX2022008925A (es) Anticuerpos anti-pd-l1.
MX2019012606A (es) Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.
PH12022553489A1 (en) Antibodies binding to cd3 and folr1
WO2020185796A9 (en) High avidity wt1 t cell receptors and uses thereof
PE20211643A1 (es) Inmunoterapia con peptidos restringidos a a 01 y una combinacion de peptidos contra el cancer y metodos relacionados
CR20230025A (es) Muteínas de il-10 y proteínas de fusión de las mismas referencia cruzada a solicitudes relacionadas
MX2025001237A (es) Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias
CL2021000177A1 (es) Péptidos, combinaciones de péptidos, células y kits para el uso en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201802360)
WO2023015229A3 (en) Sars-cov-2 virus-like particles
Flaherty et al. H (Tla) system: Identification of two new loci, H-31 and H-32, and alleles
MX2024001214A (es) Metodos y composiciones para tratar cancer.
ATE412763T1 (de) Antikörper-abhängige vergrösserung der alphavirus-infektvität